NCT01213641 - Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Cryopyrin-associated Periodic Syndromes (CAPS)Familial Cold Autoinflam Syn (FCAS)Muckle-wells Syn (MWS)Neonatal Onset Multisystem Inflam Disease (NOMID)

Trial Locations (17)

31904

Allergy Center at Brookstone, Columbus

60612

Rush Presbyterian - St. Lukes Medical Center, Chicago

72205

Little Rock Allergy and Asthma Clinic, Little Rock

Unknown

Novartis Investigative site, Bregenz

Novartis Investigative site, Vienna

Novartis Investigative site, Dresden

Novartis Investigative site, Hamburg

Novartis Investigative site, Heidelberg

Novartis Investigative site, Herne

Novartis Investigative site, Kiel

Novartis Investigative site, Schweinfurt

Novartis Investigative site, Tübingen

Novartis Investigative site, Oslo

Novartis Investigative site, Aarau

Novartis Investigative site, Basel

Novartis Investigative site, Geneva

Novartis Investigative site, Lausanne